Sherpa Healthcare Partners

AiLian Health is a digital healthcare service platform. Based on the medical supply chain and medical big data,

New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.

Kunwei Technology manufactures high-precision force sensors (six-axis force sensors) as well as force control systems. It is involved in the research and development, manufacturing, sales, and technological promotion of intelligent force sensors, as well as the development of force sensor products for the robot and other intelligent equipment industries. It provides force measurement systems as well as goods connected to measurement and other industries.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software.

Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

ZWI Therapeutics is a biotechnology company focused on enhancing the efficacy and reducing the immunogenicity of protein therapeutics. The company is developing an advanced polymer designed to improve pharmacokinetics and facilitate the creation of nanoparticles and hydrogels. Utilizing machine learning, ZWI Therapeutics aims to identify and develop immunotherapies that are effective while minimizing the risk of adverse immune responses. This innovative approach has the potential to lead to new treatments for cancer, autoimmune diseases, and other conditions, ultimately providing patients with safer and more effective therapeutic options.

Astra Space, Inc. is a technology company based in Alameda, California, that specializes in designing and building rockets for satellite delivery and launch services. Founded in 2004 and originally known as Ventions LLC, the company rebranded in 2016 and aims to provide accessible and affordable access to space. Astra offers online reservations for payload deliveries to both sun-synchronous and low inclination orbits, with a focus on dedicated launch services for payloads ranging from 50 kg to 150 kg. The business is divided into two segments: Launch Services, which provides rapid global launch capabilities, and Space Products, which includes the development of space products tailored to customer needs for successful satellite launches. Astra operates test facilities to support its operations and is committed to facilitating frequent access to space for satellite operators and governments.

Lifeshield Medical focuses on life support systems. The current products include a new generation of in vivo interventional cardiac support systems, extracorporeal carbon dioxide removal systems (ECCO2R) for the treatment of severe COPD and ECMO extracorporeal membrane oxygenation systems. The company is actively cooperating with domestic clinicians and continues to develop and industrialize several innovative life support system products and solutions such as heart, brain, lung, liver, and kidney to meet the clinical needs of the Chinese and EU markets and serve more patients.

GRIT Biotechnology, established in 2019 and based in Shanghai, China, specializes in the research and development of Tumor Infiltration Lymphocytes (TIL) immunotherapy for treating solid tumors. The company aims to enhance cancer therapies by focusing on this innovative approach.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

New Vision Medical is an IT infrastructure service provider that offers clinical trial-related digital platforms and services.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Danatlas is a pharmaceutical company that develops drugs designed for oncology treatment. It also provides drug research and development in the fields of cancer, inflammation, blood, and metabolic diseases.

BlissBio is a biopharmaceutical company dedicated to the development of innovative drugs for tumor targeting and immunotherapy. The company specializes in creating pharmaceuticals that utilize antibody-drug conjugate (ADC) and site-specific conjugate technology platforms, which are supported by independent intellectual property rights. These platforms enable BlissBio to develop and industrialize advanced anti-tumor therapies aimed at improving treatment outcomes for cancer patients. Through its focus on targeted therapies, BlissBio aims to contribute significantly to the field of oncology with its bio-innovative drug solutions.

Huihe Healthcare, founded in 2019 and based in Shanghai, China, focuses on the development and research of medical devices for structural heart diseases. The company is dedicated to creating innovative intervention devices, including systems for tricuspid valve repair, aimed at offering effective solutions for patients suffering from various heart conditions. Through its commitment to research and development, Huihe Healthcare strives to advance medical technology in the field of cardiology.

Insight Lifetech is a medical technology company focused on developing and manufacturing innovative solutions for the diagnosis and treatment of cardiovascular diseases. The company has established a comprehensive platform that integrates research and development, manufacturing, and commercialization, facilitating collaboration across its operations. This synergy accelerates product development, enhances cost-efficiency, and fosters innovation. Notably, Insight Lifetech developed the first domestic fractional flow reserve (FFR) system in China, which received approval from the National Medical Products Administration. Through its high-quality medical devices and advanced technologies, the company aims to provide reliable precision in cardiovascular diagnosis and therapy, ultimately enabling physicians to save and improve patients' lives.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

Developer of edible microbial synthetic protein food intended to provide new form of protein sources. The company focuses on the research, development and industrialization of new microbial proteins and biosynthetic proteins, enabling clients with safe, nutritious and delicious microbial substitute protein artificial food, while lowering carbon emissions.

Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

RayKol is a high-tech enterprise based in China that specializes in developing automated and intelligent solutions for laboratory environments. The company focuses on improving efficiency within the inspection and testing industry, with core operations spanning food safety, environmental protection, and life sciences. RayKol offers a comprehensive range of services, including after-sales support, training, demonstrations, and project collaboration. By integrating advanced technologies such as machine vision and motion control, the company delivers modular and fully automated systems tailored to laboratory needs. This approach enables RayKol to provide one-stop solutions that enhance automation and intelligence in laboratory processes, catering to the evolving demands of its customers.

Starna Therapeutics is a biotechnology company dedicated to the development of innovative drugs centered around RNA technology. The company boasts an advanced RNA and organ-selective delivery platform, supported by independent intellectual property rights. Starna Therapeutics focuses on addressing unmet clinical needs through its extensive research and development pipeline, which encompasses a range of therapeutic areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its expertise in RNA technology, Starna Therapeutics aims to create effective solutions for various health challenges.

HuidaGene Therapeutics Co., Ltd., established in 2018, is a Shanghai-based biotechnology company specializing in the research and development of gene therapies for single-gene disorders and neurodegenerative diseases. The company employs its proprietary CRISPR-based, AI-driven HG-PRECISE platform to create potentially curative treatments. HuidaGene's clinical pipeline includes therapies for RPE65-associated retinal disease (HG004), neovascular age-related macular degeneration (nAMD) (HG202), MECP2 duplication syndrome (HG204), and Duchenne muscular dystrophy (DMD) (HG302). Additionally, the company has preclinical programs focused on therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Cataya Bio (Shanghai) Co., Ltd. is a biotechnology company focused on developing synthetic biological products for various industries. Utilizing an advanced engineering biology platform, Cataya Bio engineers microbes and implements clean fermentation processes to produce high-purity products efficiently and sustainably. The company aims to facilitate the transition from petroleum-based materials to natural and sustainable raw materials, addressing critical global challenges such as environmental preservation, carbon emissions, and climate change. Through its innovative approach, Cataya Bio provides clients with effective solutions for sourcing raw materials that align with contemporary sustainability goals.

Shenji Bio focuses on the research and development of fundamental raw materials such as nucleosides, nucleotides, diagnostic antigens, and antibodies. As a development direction, Shenji Bio provides cost-effective products and addresses clinical unmet needs. It has gradually entered the upstream core raw material fields of IVD, mRNA, CGT, and other industries, and has established a high-quality key common technology platform to provide overall solutions for the life science field's development.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

UniXell Biotechnology is a developer of cell therapy focused on addressing unmet medical needs through human pluripotent stem cell technology. The company specializes in creating innovative treatments for neurodegenerative diseases, rare diseases, and tumors. Utilizing its proprietary platforms, UniXell Biotechnology has advanced capabilities in stem cell preparation, cultivation, differentiation, and gene editing. Key technologies include reprogramming techniques, stem cell differentiation, SISBAR pedigree tracing, and high-precision gene editing, which collectively aim to provide effective therapeutic solutions for patients suffering from challenging medical conditions.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

Leadsynbio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

MindRank is an artificial intelligence (AI)-driven drug discovery company focused on accelerating the development of small molecule medicines that offer unique clinical benefits. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, MindRank enhances the drug discovery process by providing rapid recommendations for cost-effective synthesis routes and effective drug design solutions. The company's innovative approach aims to streamline the pathway from compound identification to therapeutic application, ultimately improving healthcare outcomes through advanced pharmaceutical development.

Starna Therapeutics is a biotechnology company dedicated to the development of innovative drugs centered around RNA technology. The company boasts an advanced RNA and organ-selective delivery platform, supported by independent intellectual property rights. Starna Therapeutics focuses on addressing unmet clinical needs through its extensive research and development pipeline, which encompasses a range of therapeutic areas, including vaccines for infectious diseases, tumor immunology, and metabolic disorders. By leveraging its expertise in RNA technology, Starna Therapeutics aims to create effective solutions for various health challenges.

BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.

Sepax Technologies is a biotechnology company specializing in the development of chromatography products for the separation and purification of pharmaceuticals and biologics. The firm provides a variety of products, including liquid chromatography columns, bulk resins, and systems that support multiple modalities such as size exclusion chromatography, ion exchange, hydrophobic interaction chromatography, affinity chromatography, and reversed-phase chromatography. By offering these innovative solutions, Sepax Technologies enables biological researchers and scientists to achieve high-resolution, high-efficiency, and high-recovery separations of proteins, oligonucleotides, peptides, and other biomolecules, thus advancing research and development in the life sciences sector.

Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics aimed at treating cancer. Founded in 2021 and based in Los Angeles, CA, the company employs a strategic approach to immune response, ensuring that strong reactions to cancerous threats are achieved while preserving the body's natural mechanisms that protect healthy tissues. This method positions Fuse Biotherapeutics to create effective new treatment options that may outperform existing therapies in the oncology landscape.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, founded in 2009. The company specializes in providing research and development services to facilitate drug discovery. Its offerings include recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. Wuxi Biortus operates five advanced research platforms, including X-ray crystallography and cryo-electron microscopy, aimed at delivering high-quality R&D services to clients. The organization is known for its innovative approaches, with several techniques developed by its research team receiving patents. Wuxi Biortus is a subsidiary of Jiangsu Shuangliang Group Company Ltd.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

CashBackApp is a financial technology company that specializes in enhancing customer loyalty for fast-moving consumer goods (FMCG) companies. By partnering with various brands and retailers, CashBackApp enables consumers to earn cashback through M-Pesa on their everyday purchases. The application serves as a platform for FMCG companies to incentivize shoppers by promoting their products and offering rewards. This approach allows clients to deploy promotional offers quickly and efficiently, driving sales through mobile channels while fostering brand loyalty among consumers.

Krinwave Technology specializes in manufacturing ultrasound imaging equipment for medical use. Its proprietary kOS imaging platform offers unparalleled deep penetration and resolution, enabling clear, detailed images from deep within the body. This technology aids doctors in early detection and diagnosis across various medical fields, including whole body, cardiac, and obstetric/gynecologic imaging.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective biomanufacturing processes. Bota has created an integrative bioengineering platform that connects biological design with scale-up manufacturing, facilitating the production of high-performing industrial compounds through advanced fermentation processes. To support its innovative solutions, Bota has established a pilot plant and manufacturing facility, which enables the company to deliver scalable industrial solutions and market-ready products. Its infrastructure is designed to assist customers and partners across various industries, including nutrition, food, personal care, and animal health. Bota Biosciences is committed to accelerating shifts toward sustainable living by leveraging its multidisciplinary team's expertise to drive impactful biotech innovations.

Neukio Biotherapeutics is a biopharmaceutical company dedicated to the development of immune cell therapies aimed at treating cancer. The company specializes in the research, development, and industrialization of allogenic immune cell drugs, particularly focusing on iPSC-CAR-NK cell products. By leveraging a combination of in-house innovation and strategic collaborations with leading partners, Neukio Biotherapeutics aims to provide effective therapeutic options for cancer patients globally. Their commitment to advancing oncology treatments positions them as a significant player in the field of immunotherapy.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Jyss Bio is a developer of disposable bioreactors and peripheral equipment.

Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

PAQ Therapeutics is a biotechnology company focused on innovating health restoration and disease treatment through the process of autophagy, which is the body's natural mechanism for cellular degradation. The company is developing a unique class of small-molecule degraders utilizing autophagosome-tethering compound technology. This approach allows for the binding of various substrates to the autophagy pathway, thereby enabling the creation of targeted therapies. By harnessing this mechanism, PAQ Therapeutics aims to provide solutions for serious diseases that currently have limited therapeutic options available to patients.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

XiSoft is a professional manufacturer specializing in informatization and data services within the health economic management sector. The company focuses on leveraging technology and services to support medical institutions by offering a smart operations management tool. This platform covers various aspects including intelligent finance, material assets, internal control, human resources, comprehensive management, event management, data services, and information platforms. XiSoft's solutions aim to facilitate the strategic implementation of medical institutions, enabling business integration and refined management.

MindRank is an artificial intelligence (AI)-driven drug discovery company focused on accelerating the development of small molecule medicines that offer unique clinical benefits. Utilizing its proprietary AI platforms, including PharmKG, Molecule Dance, and Molecule Pro, MindRank enhances the drug discovery process by providing rapid recommendations for cost-effective synthesis routes and effective drug design solutions. The company's innovative approach aims to streamline the pathway from compound identification to therapeutic application, ultimately improving healthcare outcomes through advanced pharmaceutical development.

Appia Bio is a biotechnology company dedicated to the research and development of off-the-shelf allogeneic cell therapies, with a particular focus on engineered allogeneic cell therapies for various medical indications. The company utilizes its proprietary ACUA technology platform to harness the biology of lymphocyte development, integrating chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering. This innovative approach allows Appia Bio to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes derived from hematopoietic stem cells (HSCs). By maturing and scaling healthy stem cells into invariant T-cell therapies, Appia Bio aims to provide physicians with safe and targeted cancer treatment options, thereby expanding patient access to advanced therapeutic solutions.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Brattea is a medical device research and development company specializing in renal denervation products aimed at addressing various health conditions, including hypertension, cancer pain, and diabetes. The company develops interventional devices that include renal artery ablation catheters, radiofrequency ablation equipment, and medical mapping systems. These products are designed to treat a range of medical issues, such as refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Through its innovative approach, Brattea aims to provide reliable solutions that improve patient outcomes and enhance the quality of care in the medical field.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

EpimAb Biotherapeutics, based in Shanghai, China, is a biopharmaceutical research and development company focused on creating innovative bispecific antibody therapeutics, particularly for immuno-oncology. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, EpimAb develops bispecific antibodies that combine the properties of two different monoclonal antibodies into a single molecule. This unique approach aims to address the limitations of traditional antibody therapies, offering potential solutions for various life-threatening diseases, including cancer. The company recognizes the challenges associated with developing bi-specific antibodies, such as maintaining their drug-like properties and ensuring adequate production. By advancing its pipeline of bispecific therapeutics, EpimAb seeks to meet the growing demand for effective treatment options in the pharmaceutical industry.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

CotheraBio develops innovative cancer therapies with a focus on translational oncology. It has developed its proprietary i-CR® technology platform, which is a powerful method for providing individualized drug screening and new drug development. The platform combines a high content screening system with the conditional reprogramming of primary cultured tumor cells, which enables the efficient and undifferentiated expansion of primary patient-derived tumor cells in vitro, while also preserving the tumor’s heterogeneity.

Shanhu Health is a company focused on advancing digital medicine through the development of clinical application software. It specializes in creating computerized systems that enhance clinical research processes, including interactive response technology, electronic data capture, and clinical trial management systems, all built on cloud technology. By leveraging digital intelligence, Shanhu Health accelerates drug development and offers consultancy services for risk-based monitoring and the implementation of clinical research management systems.

Vazyme Biotech Co., Ltd. is a biotechnology company founded in 2012 and based in Nanjing, China. The company specializes in the development and production of enzymes and antibodies, with applications in clinical diagnosis, molecular diagnostics, high-throughput sequencing, and life science research. Vazyme Biotech is dedicated to advancing its research and development capabilities, emphasizing functional proteins and polymer organic materials. Positioned in the National Economic and Technological Development Zone of Nanjing, the company leverages its strategic location and cutting-edge technology to innovate within the biotechnology sector.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Bota Biosciences is a global industrial biotechnology company based in Hangzhou, China, founded in 2019. The company specializes in synthetic bioengineering technology for bio-manufacturing, focusing on developing efficient, eco-friendly, and cost-effective biomanufacturing processes. Bota has created an integrative bioengineering platform that connects biological design with scale-up manufacturing, facilitating the production of high-performing industrial compounds through advanced fermentation processes. To support its innovative solutions, Bota has established a pilot plant and manufacturing facility, which enables the company to deliver scalable industrial solutions and market-ready products. Its infrastructure is designed to assist customers and partners across various industries, including nutrition, food, personal care, and animal health. Bota Biosciences is committed to accelerating shifts toward sustainable living by leveraging its multidisciplinary team's expertise to drive impactful biotech innovations.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base, specializes in high-speed and high-precision radiology imaging solutions. With a significant research and development presence in Yonyou Industrial Park and a subsidiary in Chengdu, the company focuses on static computed tomography (CT), X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision developed China's first self-designed CMOS flat panel detector, known as the Merak series, which serves a diverse range of applications across medical, industrial, and security sectors. By providing advanced technological support both domestically and internationally, Nanovision aims to enhance imaging capabilities in various fields.

KeChow Pharma, established in 2014 and headquartered in Shanghai, China, is a biopharmaceutical company specializing in novel drug discovery. It concentrates on developing targeted small molecule drugs as alternatives to existing therapies, collaborating with partners for co-development.

HuidaGene Therapeutics Co., Ltd., established in 2018, is a Shanghai-based biotechnology company specializing in the research and development of gene therapies for single-gene disorders and neurodegenerative diseases. The company employs its proprietary CRISPR-based, AI-driven HG-PRECISE platform to create potentially curative treatments. HuidaGene's clinical pipeline includes therapies for RPE65-associated retinal disease (HG004), neovascular age-related macular degeneration (nAMD) (HG202), MECP2 duplication syndrome (HG204), and Duchenne muscular dystrophy (DMD) (HG302). Additionally, the company has preclinical programs focused on therapies for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd. is a Chinese company established in February 2013 and headquartered in the Yizhuang Economic and Technological Development Zone of Beijing. It operates under the umbrella of Oriental Science and Technology Holding Group Co., Ltd., which is connected to the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. GKHT Medical Technology specializes in the distribution and direct sales of medical devices, offering a range of professional services, including warehousing logistics, distribution channel management, and hospital SPD operation management. Since its inception, the company has demonstrated significant growth, achieving a compound annual growth rate of over 50%, and it is currently pursuing an initial public offering.

Jianhai Technology is an AI whole-course management platform that provides users with post-hospital & post-diagnosis management services.

Hangzhou Joinhealth Technology Co., Ltd. specializes in developing software solutions for medical follow-up and post-hospital management. Founded in 2015 and headquartered in Hangzhou, China, the company offers a range of products including systems for hospital follow-up, VIP customer management, chronic disease management, and maternal and child health. Joinhealth Technology integrates artificial intelligence and advanced technologies like the Internet and Internet of Things to enhance patient management. By shifting the focus from disease treatment to comprehensive disease management, the company facilitates intelligent management of patients throughout their healthcare journey, from hospital care to home and potential re-admission.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

EpimAb Biotherapeutics, based in Shanghai, China, is a biopharmaceutical research and development company focused on creating innovative bispecific antibody therapeutics, particularly for immuno-oncology. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, EpimAb develops bispecific antibodies that combine the properties of two different monoclonal antibodies into a single molecule. This unique approach aims to address the limitations of traditional antibody therapies, offering potential solutions for various life-threatening diseases, including cancer. The company recognizes the challenges associated with developing bi-specific antibodies, such as maintaining their drug-like properties and ensuring adequate production. By advancing its pipeline of bispecific therapeutics, EpimAb seeks to meet the growing demand for effective treatment options in the pharmaceutical industry.

New Horizon Health is a biotechnology company based in Hangzhou, China, with an additional office in Beijing, specializing in the development of innovative technologies for early cancer detection and screening. Founded in 2015, the company primarily focuses on gastrointestinal cancers, offering products such as the ColoClear and Pupu Tube, which utilize fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. These products enable users to conduct in-home tests, allowing for the early detection of colon cancer and precancerous lesions that may not be identified through traditional blood tests. New Horizon Health aims to reduce cancer morbidity and mortality rates by promoting accessible and efficient health services, leveraging big data and artificial intelligence in its screening technologies. The company's commitment to early cancer screening reflects its mission to enhance public health by facilitating widespread access to vital diagnostic tools.

Leto Laboratories is a research-focused organization dedicated to advancing the field of protein re-engineering to address unmet medical needs, particularly in cancer and rare diseases. The company utilizes cutting-edge technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms, to facilitate the creation of innovative protein-based therapeutics. With a diverse team of experts, Leto Laboratories aims to enhance the efficacy of protein-based drugs and contribute significantly to the treatment landscape for challenging health conditions.

Yosemite Clinic is a comprehensive medical facility located in Central Pudong, Shanghai, offering a wide range of walk-in medical services. The clinic specializes in various fields, including family and internal medicine, surgery, orthopedics, dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, and rehabilitation medicine. Equipped with advanced technology, Yosemite Clinic features state-of-the-art facilities such as CT, X-ray, ultrasound, and operating rooms, ensuring high-quality care. The clinic's diverse team of medical professionals, hailing from both China and around the globe, allows it to provide services in multiple languages, including English, Japanese, Malay, Mandarin Chinese, and Cantonese. By combining a multidisciplinary approach with modern medical practices, Yosemite Clinic aims to meet the diverse healthcare needs of its patients effectively.

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Hexaell Biotechnology Co., Ltd is an innovative start-up focused on developing advanced solutions for severe liver diseases through stem cell technology and bio-artificial organs. The company has licensed cutting-edge technologies, specifically iHep and HiHep, from the Chinese Academy of Sciences, which are foundational to its approach in creating medical devices aimed at replacing liver function and treating liver failure. Hexaell's research and development efforts have led to promising clinical applications, including successful pilot studies involving six liver failure patients at leading hepatopathy centers in China. By harnessing cell differentiation and production technology, Hexaell aims to provide patients with new and effective treatment options for liver-related health challenges.

Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Wuxi Biologics is a leading global contract development and manufacturing organization (CDMO) that specializes in biologics. Established in 2014 as a result of the reorganization of WuXi PharmaTech, the company offers comprehensive solutions that support organizations in the discovery, development, and manufacturing of biologic drugs, from initial concept to commercial production. With a significant revenue of CNY 17 billion, a considerable portion of its income, approximately 47.4%, is derived from North America as of 2023. Wuxi Biologics employs a strategy that focuses on following and winning drug molecules while utilizing a dual-sourcing approach to deliver both drug products and large-scale drug substance manufacturing services. The company plays a crucial role in facilitating the development of innovative biological treatments for various diseases on a global scale.

Wag Labs, Inc. is a Los Angeles-based company that provides a mobile application designed to connect pet owners with trusted and certified dog walkers. Founded in 2014, the app allows users to schedule dog walking services in major urban areas such as Los Angeles and San Francisco. The platform offers features including real-time GPS tracking during walks, enabling pet owners to monitor their dog's activity. After each walk, users receive a detailed report card that includes a photo, notes from the walker, the distance traveled, and a summary of the dog's bathroom activities. This service aims to enhance the convenience and safety of dog walking for pet owners.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

PAQ Therapeutics is a biotechnology company focused on innovating health restoration and disease treatment through the process of autophagy, which is the body's natural mechanism for cellular degradation. The company is developing a unique class of small-molecule degraders utilizing autophagosome-tethering compound technology. This approach allows for the binding of various substrates to the autophagy pathway, thereby enabling the creation of targeted therapies. By harnessing this mechanism, PAQ Therapeutics aims to provide solutions for serious diseases that currently have limited therapeutic options available to patients.